Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
For women with hair loss, there are more treatment options than ever before — and more ways to access them, as anyone scrolling social media has likely seen firsthand. But it can be confusing.
-
President Trump is pushing drugmakers to move production back to the United States. He's upping the ante with tariffs to encourage the shift. But would tariffs on imported drugs be enough?
-
President Trump is pushing drugmakers to move production back to the United States. He's upping the ante with tariffs to encourage the shift. But would tariffs on imported drugs be enough?
-
President Trump's latest executive order on drug prices aims to lower them by bringing them into line with what other developed countries pay. Experts caution that this is no small task.
-
The action is intended to build upon the existing program for Medicare drug price negotiations, which was created by the Inflation Reduction Act that passed during the Biden administration. -
It was a chaotic week for the nation's health agencies, as layoff notices rolled in along with an order for deep cuts to contract spending. NPR's health reporters tell us what they've learned.
-
With no help from the federal government, states are trying to regulate recreational marijuana. California's Department of Cannabis Control works to keep contaminants out of joints, vapes and edibles. -
Patients who bought stockpiles of alternative GLP-1 drugs online aren't sure what to do with them after learning that the compounding pharmacy that made them didn't have the right license.
-
On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare. -
The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.
